At ESMO 2026, Tango’s pancreatic cancer dataset reinforced an emerging development playbook: targeted drug combinations aimed at biomarker-defined populations, rather than chemotherapy-centered regimens. Tango’s Phase 1/2 presentation—focused on vopimetostat plus daraxonrasib in MTAP-deleted, RAS-mutant PDAC—was reported as both high-activity and chemotherapy-free, with durability metrics highlighted alongside tolerability. Separate from the regulatory and licensing headlines, the ESMO context matters because it sets the near-term competitive landscape for PDAC combinations built around epigenetic modulation and RAS-pathway dependence. For teams watching trial read-through, early response rates and PFS durability metrics in third-line and beyond cohorts are increasingly used to prioritize which assets move into Phase 3. Tango’s disclosed plan to initiate a registrational Phase 3 in 1H 2027 added a timeline dimension, giving investors a signal on when to expect confirmation-ready data. The company’s messaging also suggested it views longer follow-up as strengthening confidence in the initial June 2026 results. Across biotech, the shared lesson is that meeting presentations are now often paired with immediate development-schedule commitments, compressing the time between early signals and late-stage planning.